Rating scales and biomarkers for CAG-repeat spinocerebellar ataxias: Implications for therapy development

Meng Ling Chen, Chih Chun Lin, Liana S. Rosenthal, Puneet Opal, Sheng Han Kuo

Research output: Contribution to journalReview articlepeer-review

Abstract

Spinocerebellar ataxias (SCAs) are a group of dominantly-inherited cerebellar ataxias, among which CAG expansion-related SCAs are most common. These diseases have very high penetrance with defined disease progression, and emerging therapies are being developed to provide either symptomatic or disease-modifying benefits. In clinical trial design, it is crucial to incorporate biomarkers to test target engagement or track disease progression in response to therapies, especially in rare diseases such as SCAs. In this article, we review the available rating scales and recent advances of biomarkers in CAG-repeat SCAs. We divided biomarkers into neuroimaging, body fluid, and physiological studies. Understanding the utility of each biomarker will facilitate the design of robust clinical trials to advance therapies for SCAs.

Original languageEnglish (US)
Article number117417
JournalJournal of the Neurological Sciences
Volume424
DOIs
StatePublished - May 15 2021

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Rating scales and biomarkers for CAG-repeat spinocerebellar ataxias: Implications for therapy development'. Together they form a unique fingerprint.

Cite this